Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Immunohistochemical staining of paraffin embedded rat spleen with purified ab92726 at a working dilution of 1/500. The secondary antibody used is HRP goat anti-rabbit IgG H&L (ab97051) at 1/500. The sample is counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.

Immunoprecipitation - Anti-CD9 antibody [EPR2949] (ab92726)

ab92726 (purified) at 1/20 immunoprecipitating CD9 in 10 μg HeLa (Lanes 1 and 2, observed at 24 kDa). Lane 3 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).

Immunohistochemical staining of paraffin embedded human tonsil with purified ab92726 at a working dilution of 1/500. The secondary antibody used is HRP goat anti-rabbit IgG H&L (ab97051) at 1/500. The sample is counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.

We have not specifically tested this Anti-CD9 antibody [EPR2949] (ab92726) as a marker of urinary exosomes but I can confirm that it can be used in western blot on mouse, rat, and human samples. Additionally, I have done a Google search and found that CD9 is indeed an exosome marker therefore it can be used as you mentioned. For more details about CD9 please see the publication below.